IS4627A - Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid - Google Patents

Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid

Info

Publication number
IS4627A
IS4627A IS4627A IS4627A IS4627A IS 4627 A IS4627 A IS 4627A IS 4627 A IS4627 A IS 4627A IS 4627 A IS4627 A IS 4627A IS 4627 A IS4627 A IS 4627A
Authority
IS
Iceland
Prior art keywords
monoglyceride
inhibitor
pharmaceutical composition
protein cleavage
cleavage catalyst
Prior art date
Application number
IS4627A
Other languages
English (en)
Other versions
IS2661B (is
Inventor
Ann Bailey Carole
Josephine Ferdinando Christine
Shah Navnit
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/616,233 external-priority patent/US6008228A/en
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of IS4627A publication Critical patent/IS4627A/is
Publication of IS2661B publication Critical patent/IS2661B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IS4627A 1995-06-06 1997-12-04 Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid IS2661B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46849395A 1995-06-06 1995-06-06
US08/616,233 US6008228A (en) 1995-06-06 1996-05-07 Pharmaceutical compositions containing proteinase inhibitors
PCT/EP1996/002431 WO1996039142A1 (en) 1995-06-06 1996-06-04 Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride

Publications (2)

Publication Number Publication Date
IS4627A true IS4627A (is) 1997-12-04
IS2661B IS2661B (is) 2010-08-15

Family

ID=27042422

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4627A IS2661B (is) 1995-06-06 1997-12-04 Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid

Country Status (27)

Country Link
EP (1) EP0831826B1 (is)
JP (1) JP3238412B2 (is)
CN (1) CN1092960C (is)
AT (1) ATE226075T1 (is)
AU (1) AU709796B2 (is)
BG (1) BG63711B1 (is)
BR (1) BR9610842A (is)
CA (1) CA2224125C (is)
CY (1) CY2373B1 (is)
CZ (1) CZ292192B6 (is)
DE (1) DE69624354T2 (is)
DK (1) DK0831826T3 (is)
EA (1) EA001413B1 (is)
ES (1) ES2182996T3 (is)
HK (1) HK1010136A1 (is)
HU (1) HU223899B1 (is)
IL (1) IL122353A0 (is)
IS (1) IS2661B (is)
MX (1) MX9709193A (is)
NO (1) NO324531B1 (is)
NZ (1) NZ311646A (is)
OA (1) OA10546A (is)
PL (1) PL184820B1 (is)
PT (1) PT831826E (is)
SK (1) SK282121B6 (is)
TR (1) TR199701541T1 (is)
WO (1) WO1996039142A1 (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0989851T3 (da) 1997-07-29 2003-01-27 Upjohn Co Selvemulgerende formulering indeholdende sure lipofile forbindelser
CN1113650C (zh) 1997-07-29 2003-07-09 法玛西雅厄普约翰美国公司 自体乳化剂形式的亲脂性化合物的药物组合物
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
CN1232244C (zh) * 1999-02-08 2005-12-21 阿尔萨公司 稳定的非水性单相粘性载体及采用该载体的制剂
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BR0202252A (pt) 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP2108705A1 (en) 2008-04-08 2009-10-14 Universität Duisburg-Essen Method for analysing the epigenetic status of the HtrA 1 gene in a biological sample
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
AU709796B2 (en) 1999-09-09
IL122353A0 (en) 1998-04-05
DK0831826T3 (da) 2003-02-03
JP3238412B2 (ja) 2001-12-17
OA10546A (en) 2002-05-29
NO975665L (no) 1998-02-05
EP0831826A1 (en) 1998-04-01
JPH10507202A (ja) 1998-07-14
SK162797A3 (en) 1998-05-06
NZ311646A (en) 2000-02-28
TR199701541T1 (xx) 1998-03-21
EA001413B1 (ru) 2001-02-26
PL184820B1 (pl) 2002-12-31
IS2661B (is) 2010-08-15
SK282121B6 (sk) 2001-11-06
PT831826E (pt) 2003-02-28
HU223899B1 (hu) 2005-03-29
AU6300496A (en) 1996-12-24
CZ292192B6 (cs) 2003-08-13
EP0831826B1 (en) 2002-10-16
PL323860A1 (en) 1998-04-27
BG102106A (en) 1998-08-31
HK1010136A1 (en) 1999-06-17
DE69624354D1 (de) 2002-11-21
MX9709193A (es) 1998-03-31
CN1186434A (zh) 1998-07-01
CY2373B1 (en) 2004-06-04
BG63711B1 (bg) 2002-10-31
DE69624354T2 (de) 2003-06-05
CA2224125A1 (en) 1996-12-12
WO1996039142A1 (en) 1996-12-12
NO324531B1 (no) 2007-11-12
EA199800023A1 (ru) 1998-08-27
CZ380397A3 (cs) 1998-03-18
ES2182996T3 (es) 2003-03-16
NO975665D0 (no) 1997-12-05
ATE226075T1 (de) 2002-11-15
CN1092960C (zh) 2002-10-23
BR9610842A (pt) 1999-07-13
HUP9801905A2 (hu) 1999-05-28
HUP9801905A3 (en) 2001-04-28
CA2224125C (en) 2004-09-28

Similar Documents

Publication Publication Date Title
IS4627A (is) Lyfjablanda sem samanstendur af hindra fyrir proteinkljúfandi hvata og monoglycerid
HK1016610A1 (en) Prodrugs of thrombin inhibitors.
AU2012199A (en) Prodrugs of aspartyl protease inhibitors
ZA9811830B (en) Prodrugs of aspartyl protease inhibitors.
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
FI973360A0 (fi) Uusia dipeptidisiä amidiineja trombiininestäjiksi
EE200000386A (et) Aspartüülproteaasi inhibiitorite eelravimid
AU7473398A (en) Inhibitors of protein isoprenyl transferases
LV11951A (lv) Mikrosomalo trigliceridu transportproteinu inhibitors
NO20006716D0 (no) Proteaseinhibitorer
ATE218336T1 (de) Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
AU7117496A (en) Peptide inhibitor for viral protease derived from the transframe region of the gag-pol gene
MY116525A (en) Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
IT1307928B1 (it) Metodo di sintesi di nitrossimetilfenil esteri di derivatidell'aspirina.
HRP20030983B1 (en) Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
DK0842185T3 (da) Ara-C-derivater
NO20004664L (no) FremgangsmÕte for fremstilling av HIV proteaseinhibitorer
AU6678398A (en) Inhibitors of isoprenyl transferase
AU1279899A (en) N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors
AU8297698A (en) Inhibitors of neutrophil mediated oxidant production
ECSP961778A (es) Composiciones que incrementan la biodisponibilidad de inhibidores de proteinasa
TNSN96081A1 (fr) Composition antiretrovirale